[email protected]
CDI - Contrive Datum Insights
Healthcare Services

Genomics Services MarketSize, Share & Industry Analysis, 2026-2034By Service TypeBy Sequencing TechnologyBy ApplicationBy Workflow StageBy End UserBy Sample TypeBy Disease AreaBy Service Provider ModelBy Project ScaleBy Delivery ModelBy Regulatory and Accreditation Status

Full title & scope — all 11 axes with their segments

Genomics Services Market Size, Share & Industry Analysis, By Service Type (Next-Generation Sequencing Services, Sanger Sequencing Services, Microarray Services, Genotyping Services, Epigenomics Services, Bioinformatics and Data Analysis Services, Other Genomics Services), By Sequencing Technology (Short-Read Sequencing, Long-Read Sequencing, Sanger Sequencing, Microarray-Based Platforms, Real-Time PCR and Digital PCR), By Application (Research, Clinical Diagnostics, Drug Discovery and Development, Precision and Personalized Medicine, Agriculture and Animal Genomics, Consumer Genomics), By Workflow Stage (Sample Preparation and Library Construction, Sequencing / Data Generation, Primary and Secondary Analysis, Tertiary Analysis and Interpretation, Reporting and Data Management), By End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals and Diagnostic Laboratories, Government and Public Health Agencies, Agricultural and Food Companies, Direct-to-Consumer), By Sample Type (Blood, Tissue, Saliva and Buccal Swab, Microbial and Environmental Samples, Plant and Animal Samples, Other Sample Types), By Disease Area (Oncology, Rare and Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Other Disease Areas), By Service Provider Model (Core Facility and Academic Service Labs, Commercial Genomics Service Providers, Instrument Vendor Service Divisions, Clinical Reference Laboratories, Contract Research Organization Genomics Units), By Project Scale (Single-Sample and Small-Batch Projects, Mid-Scale Cohort Studies, Population-Scale and Biobank Programs, Ongoing Routine Testing Volumes), By Delivery Model (Outsourced Service Contracts, Fee-for-Service Per Sample, Subscription and Bundled Analysis Plans, Partnership and Collaborative Programs), By Regulatory and Accreditation Status (Research Use Only, CLIA / CAP Certified Clinical, ISO 15189 Accredited, CE-IVD / FDA-Cleared or Approved Assays), and Regional Forecast, 2026-2034

Last Updated: Nov 18, 2026Format: PDFReport ID: CDI-248907
Methodology

How the estimates were built: data sources, modelling approach and validation steps.

Research approach

A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.

Market size estimation, this report

The market was built upward from sample volumes and realised prices. For each service line we estimated annual sample throughput by application and end user, using sequencing run output, genotyping array shipments, public registry counts of tests and cohort project awards, then applied realised per-sample prices that differ by technology, read depth and turnaround. Bioinformatics revenue was built from projects attached to sequencing orders plus standalone analysis contracts. The result was checked against revenue disclosed by listed service providers and the services lines of instrument makers, adjusted to remove product sales. Where the check and the build disagreed, the bottom-up assumption on volume or price was reviewed and corrected; the disclosed figures were not averaged into the estimate.

The four stages

The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.

1
Scope and segmentation
2
Bottom-up sizing
3
Reconciliation
4
Forecast

What the build rests on, and what checks it

The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.

The bottom-up build rests on
  • Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
  • Realised pricing by tier and channel, rather than one blended average applied across the whole market
  • Take-up and frequency: how much of the addressable base buys, and how often it repeats
The build is checked against
  • Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
  • Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
  • Trade and customs flows, where the product crosses borders in a separately recorded form
Bottom-up sequence
1
Size the base
2
Apply take-up
3
Apply frequency
4
Apply realised price
Reconciliation sequence
1
Gather disclosed revenue
2
Strip out-of-scope lines
3
Compare against the build
4
Correct the assumption

Data sources

Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.

Primary — who is interviewed
  • Commercial and product leadership at the companies that supply the market
  • Procurement and specification leads at the organisations that buy it
  • Distributors, integrators and channel partners, where the market is served indirectly
  • Regulatory and standards specialists, where approval governs what can be sold at all
Secondary — what is read
  • Company filings, annual reports and investor disclosure
  • Government statistics, customs records and regulatory registers
  • Trade association output and standards-body publications
  • Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Primary research design, this report

Primary research targets the people who buy and run outsourced genomics work: laboratory directors and core facility managers, procurement and sourcing leads at pharmaceutical and biotechnology companies, contract research organization project managers, clinical laboratory directors, bioinformatics heads and genetic counselling leads. Commercial and operations executives at service providers add views on capacity utilisation, turnaround and pricing. Conversations emphasise North America, Europe and the major Asian sequencing hubs, with shorter coverage of the Middle East and Latin America where national genome programs and new laboratory builds are shaping demand. Responses are used to test volume, price and outsourcing assumptions, not to set the market total.

Secondary sources, this report

Desk research rests on the NCBI Sequence Read Archive submission statistics for sequencing activity, the CMS Clinical Laboratory Fee Schedule and the CLIA laboratory registry for clinical test pricing and laboratory counts, FDA device clearance and approval databases for regulated assays, and NIH grant award records for academic demand. Program disclosures from national genome initiatives and biobanks describe cohort sizes and contract awards. Annual reports, securities filings and investor presentations of listed providers supply segment revenue and pricing commentary, and accreditation body directories help size the regulated laboratory base.

Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.

Forecasting

The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.

Forecast approach, this report

The forecast projects sample volumes by application and end user, then applies price paths by technology. Volume growth follows adoption of tumor profiling and rare disease sequencing in routine care, expansion of national genome and biobank programs, and pharmaceutical use of genomic data in trial design. Prices decline per sample as platform throughput rises, partly offset by a mix shift toward deeper coverage, long-read work and interpreted reporting. For the forecast to hold, reimbursement must keep extending to genomic tests, data transfer rules must stay workable for outsourced providers, and falling sequencing cost must expand order volume faster than it compresses price. Short-term softness in academic orders is normalised as a pause, not a change in trend.

Triangulation and validation

No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.

Validation, this report

Outputs were back-tested by running the volume and price model on the historical years and comparing the implied revenue trajectory with the growth recorded across disclosed provider revenue. Segment shifts, such as the rising weight of bioinformatics and long-read work, were reviewed with industry experts for direction and pace. Sensitivity runs varied sample volume growth, price decline per sample and the share of work kept in-house, and the effect on the total was checked against the bull and bear paths. Country sizes were reconciled to regional totals, and each segmentation axis was confirmed to add up to the market in the base year and the final forecast year.

Confidence and limitations

Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.

Confidence framing, this report

Confidence is firmest for sequencing services in North America and Europe, where listed providers and public registries disclose volumes and prices, and for clinical testing tied to accredited laboratories. It is weaker for Asia Pacific, where private laboratories report little, for consumer and agricultural work, and for bioinformatics sold inside bundled contracts. Revisions would follow from a sharp change in reimbursement, tighter data localisation rules, a step change in sequencing cost, or a shift of academic and pharmaceutical work back in-house. A band of plus or minus fifteen percent around the base year total is appropriate.

Scope

Questions This Report Answers

6 questions
01

What is the market size and growth rate, globally and by region?

02

How is the market segmented, and which segments lead?

03

Which regions and countries are covered, and how do they compare?

04

What are the key drivers, restraints, opportunities and challenges?

05

Who are the leading companies operating in this market?

06

What trends are expected to shape the market through the forecast period?

Questions

Frequently Asked Questions

01What is the Genomics Services Market projected to reach?

USD 36.6 USD Billion by 2034, CAGR 11.12%

02What years does this report cover?

Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.

03Which regions are covered?

North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

04Which region accounted for the largest market share?

North America leads with 41% of global revenue through 2034.

05Which segment leads the market?

Next-Generation Sequencing Services is the largest line by service type, at 46% of revenue in 2025.

06Who are the key companies profiled?

Illumina, Inc., Thermo Fisher Scientific Inc., BGI Genomics Co., Ltd., Eurofins Scientific SE, Macrogen, Inc., Psomagen, Inc., Azenta Life Sciences (GENEWIZ), Agilent Technologies, Inc., QIAGEN N.V., Novogene Co., Ltd., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, Element Biosciences, Inc., 10x Genomics, Inc., Revvity, Inc., Charles River Laboratories International, Inc., Fulgent Genetics, Inc., GeneDx Holdings Corp., Invitae Corporation, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Integrated DNA Technologies, Inc., CD Genomics, Genome Quebec / Genome Sciences Centre, Admera Health, LLC, Theragen Bio Co., Ltd., GenScript Biotech Corporation, Personalis, Inc.. Full profiles are part of the paid report.

07Can the segmentation be customized?

Yes. Custom data cuts by geography, segment, or competitor set are available on request.

425+
Dedicated research analysts
1,200+
Reports published
Why CDI

Why choose CDI

Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available

Need this report shaped around your question?

The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.

Most licences include 30–60 hours of customization at no extra cost. See what each licence includes

Request customization

Additional Companies

Add competitors, suppliers or the peer set you benchmark against to the companies already covered.

Deeper Competitive View

Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.

Extra Segment Splits

Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.

Application Focus

Narrow the analysis to the specific use cases and end users your team actually sells into.

Different Time Frame

Move the base year, or widen the historical and forecast windows the study is built on.

Country-Level Detail

Go below region level into the individual countries that matter to you, rather than the standard geography split.